ArticleOdontology2026
Relationship between bone resorption and sclerostin regulation in apical periodontitis lesions.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the relationship between gingival crevicular fluid (GCF) and serum sclerostin and PGE2 levels and the inflammatory bone resorption associated with chronic apical periodontitis (AP) as well as the correlation between sclerostin regulation and RANKL and MMP-9 levels. Ninety participants were divided into three groups based on PAI scores, as follows: Group 1 (control group, PAI 1-2, n:35); Group 2 (PAI 3-4, n:35); Group 3 (PAI 5 in at least 1 tooth, n:55). Sclerostin, PGE2, RANKL, and MMP-9 levels were measured in the serum and GCF of all participants. GCF sclerostin, RANKL, and PGE2 levels of Group 3 were significantly higher than those of Groups 1 and 2 (75.8 ± 43.3, 37.0 ± 6.4 and 42.7 ± 8.2 ng/mL, p < 0.0001; 319 ± 167, 244 ± 41 and 248 ± 49 ng/L, p = 0.0029; 193 ± 87, 141 ± 90 and 137 ± 79 ng/L, p = 0.0028, respectively for Groups 3, 2, and 1). GCF MMP-9 levels of Group 3 were significantly higher than those of Group 1 (465 ± 162 and 384 ± 44 ng/mL, p = 0.0340). Group 3 also had elevated serum sclerostin and PGE-2 levels, but the differences between groups were less pronounced in serum than in GCF (p < 0.05). In the ROC analysis performed for the diagnostic performance of abscess formation in AP, the sensitivity of the GCF sclerostin and GCF PGE2 tests was determined as 65.5% and 72.7%, specificity as 98.6% and 68.6%, and AUC as 0.768 and 0.712, respectively (p < 0.0001). Both GCF sclerostin and PGE-2 independently showed close relationships with PAI-abscess scores used to determine AP severity and they can be used in combination for diagnosing and monitoring AP-related bone resorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.